Compare Cassava Sciences Inc (FLNA) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Johnson Controls International PLC — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Johnson Controls International PLC trades at $156.33 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 2367.5× Cassava Sciences Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Johnson Controls International PLC for 65 Days on average.
| FLNA | JCI | |
|---|---|---|
Market Cap | $39.40M | $93.28B |
Volume | 759,018 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $158.76 |
52-Week Low | $0.68 | $105.55 |
Typical Hold Time | 37 Days | 65 Days |
Enterprise Value | -$43.28M | $102.12B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
JCI trades at $155.93, down 1.78% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by 10% organic sales growth and a record $21 billion backlog. Profitability remains solid with a 14.32% net income margin and 24.42% ROE.
The stock offers upside to the $172.50 consensus price target, supported by strong fundamentals and institutional accumulation. Risks include elevated valuation multiples (P/E 43.38) and potential macroeconomic pressures on industrial demand. Continued execution on data center and building systems growth is key for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
